Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review

Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review

Show other versions (1)

Cisplatin has a pivotal role in the treatment of non-small cell lung cancer (NSCLC). However, it is associated with a number of serious and unpleasant side effects (nausea-vomiting, myelo-suppression, neuro-toxicity and renal function impairment). To overcome these limitations, most clinicians have...

Full description

Bibliographic Details
Main Authors:	Marcello Tiseo, Andrea Ardizzoni
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2011-12-01
Series:	Oncology Reviews
Subjects:	Non-small cell lung cancer - Cisplatin - Carboplatin
Online Access:	http://oncologyreviews.org/index.php/or/article/view/151

Similar Items

Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review
by: Marcello Tiseo, et al.
Published: (2011-12-01)

Pemetrexed Combined with Cisplatin or Carboplatin Regimen in the Treatment of Advanced Recurrent or Metastasis Non-small Cell Lung Cancer: Analysis of 63 Cases
by: Wei WANG, et al.
Published: (2011-01-01)

Cost-effectiveness analysis of paclitaxel + carboplatin vs. alternative combinations in the treatment of non-small cell lung cancer
by: Mario Eandi
Published: (2006-09-01)

Hypersensitivity and cross-reactivity to cisplatin and carboplatin
by: Gholamreza Faridaalaee, et al.
Published: (2016-07-01)

Switching cisplatin to carboplatin in chemotherapy for metastatic penile cancer in a patient intolerant to cisplatin
by: Keita Sekine, et al.
Published: (2024-11-01)

Chemotherapy for small cell lung cancer: a comprehensive review
by: Syed Mustafa Karim, et al.
Published: (2012-04-01)

Advanced non-small cell lung cancer in elderly patients: The standard every 3-weeks versus weekly paclitaxel with carboplatin
by: Hala Mohamed El-Shenshawy, et al.
Published: (2012-10-01)

Syndrome of Inappropriate Secretion of Antidiuretic Hormone Caused by Carboplatin After Switching from Cisplatin in a Metastatic Urethral Cancer Patient
by: Yosuke Sugiyama, et al.
Published: (2017-05-01)

Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis
by: Yingkai Chen, et al.
Published: (2022-06-01)

Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies
by: Raymond P. Perez, et al.
Published: (2019-12-01)

A Potentially Less Nephrotoxicity of Carboplatin Over Cisplatin as Radiosensitizer in Head-neck Cancer
by: Mahfujul Ahmed Riad
Published: (2022-08-01)

Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer
by: Nicole F. Laslett, et al.
Published: (2018-07-01)

Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC
by: Laksmi Wulandari, et al.
Published: (2022-01-01)

A phase II feasibility study of carboplatin and nab‐paclitaxel for advanced non‐small cell lung cancer patients with interstitial lung disease (YLOG0114)
by: Hiroyuki Sakashita, et al.
Published: (2022-05-01)

Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease
by: Igawa S, et al.
Published: (2018-12-01)

A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non‐small cell lung cancer (LOGIK1902)
by: Taishi Harada, et al.
Published: (2024-10-01)

Carboplatin-Induced Bilateral Papilledema: A Case Report
by: N. Fischer, et al.
Published: (2009-04-01)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
by: Kazuma Sugimoto, et al.
Published: (2022-11-01)

The effect of choice of platinum on survival and factors affecting survival in metastatic small cell lung cancer: A Single Center Experience
by: Ayşegül Sakin, et al.
Published: (2021-01-01)

Efficacy Comparison Between Weekly and Triweekly Regimens of Carboplatin-paclitaxel in Non-small Cell Lung Cancer
by: Serdar ATA, et al.
Published: (2023-09-01)

Comparison of survival and adverse effect profile in patients with esophageal cancer treated with the combination of carboplatin and paclitaxel vs. 5-flourouracil and cisplatin
by: N. Nisar, et al.
Published: (2022-09-01)

First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: Results of the NEPTUN study
by: Tobias Dechow, et al.
Published: (2021-11-01)

PHASE II STUDY OF GEMCITABINE AND CISPLATIN IN ADVANCED NON-SMALL CELL LUNG CANCER
by: M. Hoseinzadeh Mollayosefy, et al.
Published: (2006-06-01)

PHASE II STUDY OF GEMCITABINE AND CISPLATIN IN ADVANCED NON-SMALL CELL LUNG CANCER
by: M. Hoseinzadeh Mollayosefy, et al.
Published: (2006-04-01)

A Meta-Analysis of Platinum Plus Gemcitabine or Vinorelbine for Advanced Non-small Cell Lung Cancer
by: Guanghui GAO, et al.
Published: (2009-01-01)

Carboplatin plus nab‐paclitaxel for recurrent small cell lung cancer: A phase II study
by: Naoya Ikeda, et al.
Published: (2022-05-01)

DISSEMINATED NON SMALL-CELL LUNG CANCER: POSSIBILITIES OF DRUG THERAPY IN THE FIRST DECADE OF THE XXI CENTURY
by: A. M. Garin, et al.
Published: (2014-07-01)

DISSEMINATED NON SMALL-CELL LUNG CANCER: POSSIBILITIES OF DRUG THERAPY IN THE FIRST DECADE OF THE XXI CENTURY
by: A. M. Garin, et al.
Published: (2014-07-01)

The Clinical Analysis of Paclitaxel at Two Dose Levels plus Carboplatin as the First-line Treatment in Advanced Non-small Cell Lung Cancer
by: Jialin QIAN, et al.
Published: (2011-04-01)

Transcriptomic Profiling of Carboplatin- and Paclitaxel-Resistant Lung Adenocarcinoma Cells Reveals <i>CSF3</i> as a Potential Biomarker for the Carboplatin Plus Paclitaxel Doublet Regimens
by: Pritsana Raungrut, et al.
Published: (2024-12-01)

Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status
by: Nobuaki Mamesaya, et al.
Published: (2023-03-01)

Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab
by: Reyes Bernabé, et al.
Published: (2024-01-01)

Development and Evaluation of a Quantitative Systems Pharmacology Model for Mechanism Interpretation and Efficacy Prediction of Atezolizumab in Combination with Carboplatin and Nab-Paclitaxel in Patients with Non-Small-Cell Lung Cancer
by: Chen-Yu Wang, et al.
Published: (2024-02-01)

Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer
by: Jonathan W. Goldman, et al.
Published: (2019-11-01)

Clinical benefits of adjuvant chemotherapy with carboplatin and gemcitabine in patients with non-small cell lung cancer: a single-center retrospective study
by: Shinogu Takashima, et al.
Published: (2020-10-01)

Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus
by: Stefan Münch, et al.
Published: (2017-11-01)

Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus
by: Stefan Münch, et al.
Published: (2018-08-01)

Evaluation of toxic effects of chemotherapy in lung malignancies on cerebral white matter using diffusion tensor imaging
by: Aydin Sinem, et al.
Published: (2022-05-01)

Sensitization of cancer cells towards Cisplatin and Carboplatin by protein kinase D inhibitors through modulation of ATP7A/B (copper transport ATPases)
by: Prajit Janardhanan, et al.
Published: (2022-01-01)

Pharmacotherapy of small cell lung cancer: Current state-of-the-art
by: Tatyana A. Berezhnova, et al.
Published: (2023-03-01)